ライフサイエンスコーパス: oral glucose tolerance

1 index and individuals with normal or altered oral glucose tolerance.

2 aired fasting plasma glucose and/or impaired oral glucose tolerance.

3 a levels of GLP-1 and insulin and diminished oral glucose tolerance.

4 Oral glucose tolerance and brachial artery flow-mediated

5 gotes for ABCA1 mutations exhibited enhanced oral glucose tolerance and dramatically increased beta-c

6 Oral glucose tolerance and insulin levels were measured.

7 F508 mutants had lower body weight, improved oral glucose tolerance, and a trend toward higher insuli

8 , Simple Index Assessing Insulin Sensitivity Oral Glucose Tolerance, and HOMA-IR were high, and did n

9 tein can use RT to improve body composition, oral glucose tolerance, and skeletal muscle aPKC zeta/la

10 mic-hyperinsulinemic clamp) 442% (P < 0.01), oral glucose tolerance (area under the curve for 3-h ora

11 The RT-induced improvement in oral glucose tolerance (decreased area under the curve,

12 polypeptide (GIP), and insulin, and improved oral glucose tolerance in an RU486-insensitve manner in

13 The impaired oral glucose tolerance in diet-induced obese mice was al

14 insulin sensitivity, beta cell function, and oral glucose tolerance in nondiabetic obese adults.

15 DJB has been shown to improve oral glucose tolerance in normal rats and a genetic diab

16 However, the improvement in oral glucose tolerance, insulin sensitivity, and overall

17 eight, visceral and subcutaneous fat depots, oral glucose tolerance, insulin sensitivity, and the pla

18 tor for 10 d was well tolerated and improved oral glucose tolerance, it increased the expression of t

19 lation-based Ely Study, had glycemic status (oral glucose tolerance), lipids, insulin, anthropometry,

20 nt in those with diabetes; those with normal oral glucose tolerance lost 9.1+/-3.7 kg of fat (18+/-3

21 with lower CNS penetration, and activity in oral glucose tolerance studies was demonstrated.

22 ycemia, preferred strategies were the 2-hour oral glucose tolerance test (100% effectiveness; $390 pe

23 g therapy at any examination, or with a 75-g oral glucose tolerance test (1980 World Health Organizat

24 spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the

25 rement (DeltaI(30-0)/DeltaG(30-0)) during an oral glucose tolerance test (a surrogate for insulin sec

26 4 and glucose area under the curve during an oral glucose tolerance test (additive model, P = 0.022;

27 d increased fasting plasma insulin during an oral glucose tolerance test (all P < 0.01), as well as a

28 38; P = .03), plasma glucose levels after an oral glucose tolerance test (Hedges g = 0.61; 95% CI, 0.

29 icting to identifying IGT/NODAT using 2-hour oral glucose tolerance test (n = 66), fructosamine was t

30 these autoantibodies (Ab-), had an abnormal oral glucose tolerance test (OGTT) (P = 0.03) before and

31 years from prediabetes onset and the average oral glucose tolerance test (OGTT) 2-h glucose measureme

32 Study participants were phenotyped by an oral glucose tolerance test (OGTT) and an intravenous gl

33 mpared beta-cell function assessed during an oral glucose tolerance test (OGTT) and an isoglycemic in

34 s with varying glucose tolerance received an oral glucose tolerance test (OGTT) and euglycemic insuli

35 20 type 2 diabetic patients received a 75-g oral glucose tolerance test (OGTT) and euglycemic insuli

36 cose tracer and labeled glucose infusion and oral glucose tolerance test (OGTT) before and 6 months a

37 owing glucose beverage consumption during an oral glucose tolerance test (OGTT) for 400 northern Euro

38 litus (GDM) is conventionally confirmed with oral glucose tolerance test (OGTT) in 24 to 28 weeks of

39 venous glucose tolerance test (IVGTT) and by oral glucose tolerance test (OGTT) in 3 different sessio

40 , based on insulin levels measured during an oral glucose tolerance test (OGTT) in 552 nondiabetic pa

41 c evaluation of biochemical changes after an oral glucose tolerance test (OGTT) in a community-based

42 on lower (P < 0.05) during the meal than the oral glucose tolerance test (OGTT) in all subgroups rega

43 exhibited pronounced in vivo efficacy in an oral glucose tolerance test (OGTT) in lean mice.

44 as a compound that displayed activity in an oral glucose tolerance test (OGTT) in normal and diabeti

45 fasting and postprandial lipids and after an oral glucose tolerance test (OGTT) in the European Ather

46 All individuals underwent a 75-g oral glucose tolerance test (OGTT) in which we measured

47 ell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period

48 e obtained, in addition to 0-hour and 2-hour oral glucose tolerance test (OGTT) results, with measure

49 We analyzed the results of an oral glucose tolerance test (OGTT) routinely performed b

50 /dl relative to control HF animals during an oral glucose tolerance test (OGTT) such that levels were

51 The aim of this study was to use an oral glucose tolerance test (OGTT) to risk stratify for

52 zed by the following: 1) associations with 5 oral glucose tolerance test (OGTT) traits in 427 nondiab

53 in and glucose were monitored weekly, and an oral glucose tolerance test (OGTT) was performed at stud

54 The 5-hour oral glucose tolerance test (OGTT) was performed to asse

55 h positive O'Sullivan test (POT) results, an oral glucose tolerance test (OGTT) was performed to diag

56 An oral glucose tolerance test (OGTT) was used to evaluate

57 ons of glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in indi

58 the insulin-to-glucose ratio (IGR) at 30-min oral glucose tolerance test (OGTT), a frequently used su

59 atched control participants and underwent an oral glucose tolerance test (OGTT), a hypoglycemia quest

60 at reducing peak glucose levels in an acute oral glucose tolerance test (OGTT), but this effect was

61 e in blood glucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first betwe

62 by blood glucose and insulin responses to an oral glucose tolerance test (OGTT), insulin sensitivity

63 s with wild-type genotype (CC) underwent 5-h oral glucose tolerance test (OGTT), isoglycemic intraven

64 Herein we describe oral glucose tolerance test (OGTT)-modeled beta-cell fun

65 lucose-lowering actions were tested after an oral glucose tolerance test (OGTT).

66 dices of beta-cell function derived from the oral glucose tolerance test (OGTT).

67 frank diabetes based on the rarely utilized oral glucose tolerance test (OGTT).

68 A total of 319 subjects were studied with an oral glucose tolerance test (OGTT).

69 ging and glucose and insulin responses to an oral glucose tolerance test (OGTT).

70 ears; BMI 29.0 +/- 0.3 kg/m(2)) underwent an oral glucose tolerance test (OGTT).

71 and 2-h insulin concentrations after a 75-g oral glucose tolerance test (OGTT).

72 g) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).

73 se >/= 11.1 mmol/L (>/= 200 mg/dL) during an oral glucose tolerance test (OGTT).

74 ized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).

75 At wk 15, pigs were subjected to an oral glucose tolerance test (OGTT); blood glucose increa

76 nal age at delivery, parity, maternal age at oral glucose tolerance test (OGTT); Model 2 adjusted for

77 with glucose area under the curve during an oral glucose tolerance test (P = 0.035 and 0.013, respec

78 n in the insulinogenic index derived from an oral glucose tolerance test (risk allele homozygotes hav

79 o glucose during the first 30 minutes of the oral glucose tolerance test 2 years later.

80 560887 was significantly associated with the oral glucose tolerance test 30-min incremental insulin r

81 ly diagnosed diabetes by 2-h glucose from an oral glucose tolerance test [OGTT] [DM2h], n = 80; newly

82 ting plasma glucose, hemoglobin A1c, and the oral glucose tolerance test all predict diabetic complic

83 ts and 10 healthy control subjects to a 75-g oral glucose tolerance test and a corresponding isoglyce

84 estionnaire, color Doppler echocardiography, oral glucose tolerance test and blood biomarkers analyse

85 d as the suppression of plasma FFA during an oral glucose tolerance test and by a low-dose insulin in

86 were gestational diabetes (diagnosed with an oral glucose tolerance test and by criteria from the Int

87 jection not only improved the response to an oral glucose tolerance test and corrected insulin signal

88 All underwent an oral glucose tolerance test and fasting lipoprotein subc

89 ose tissue biopsy, in addition to metabolic (oral glucose tolerance test and hyperinsulinemic euglyce

90 a, and disposition index were measured after oral glucose tolerance test and isoglycemic IV glucose i

91 All participants underwent a standard oral glucose tolerance test and provided detailed clinic

92 Participants underwent an oral glucose tolerance test and retinal imaging at 26-28

93 o glucose during the first 30 minutes of the oral glucose tolerance test and using the area under the

94 Nine healthy subjects consumed a 150-g oral glucose tolerance test and were infused with 500 pm

95 ant recipients without diabetes underwent an oral glucose tolerance test and were observed until prim

96 Furthermore, the oral glucose tolerance test appears to be a more sensiti

97 es of maternal metabolism obtained during an oral glucose tolerance test at approximately 28 weeks' g

98 054 adults aged 30-74 years who underwent an oral glucose tolerance test at baseline (1976-1980).

99 total body surface area burned, underwent an oral glucose tolerance test at discharge.

100 ucose and insulin will be measured during an oral glucose tolerance test at weeks 0 and 12.

101 glucose below 7 mmol/L, 2 hour glucose after oral glucose tolerance test below 11.1 mmol/L, and glyca

102 utcome measures were difference in change in oral glucose tolerance test between the groups and betwe

103 lin level, Matsuda index, and area under the oral glucose tolerance test curve (AUC) of insulin.

104 e and glucose area under the curve on 2-hour oral glucose tolerance test differed across arms (1-way

105 mes were glucose tolerance (measured with an oral glucose tolerance test given after 90 min) and meal

106 y homeostasis model assessment, and 2-h post-oral glucose tolerance test glucose and insulin levels.

107 bese adolescents with high-"normal" 2-h post-oral glucose tolerance test glucose levels display defec

108 ur plasma glucose >/=200 mg/dL during a 75-g oral glucose tolerance test had a definite diagnosis of

109 c ICA positivity had to be confirmed, and an oral glucose tolerance test had to result in nondiabetic

110 enge test (GCT) followed by a 75-gram 2-hour oral glucose tolerance test if GCT result was >/=7.8 mmo

111 -5.2]) and with 30-min plasma insulin during oral glucose tolerance test in 287 nondiabetic individua

112 ivo activity in rodents and was active in an oral glucose tolerance test in mice following oral admin

113 gnificantly reduced glucose levels during an oral glucose tolerance test in normal mice.

114 ervous system activity at rest and during an oral glucose tolerance test in obese metabolic syndrome

115 creased plasma GLP-1 concentration during an oral glucose tolerance test in rats.

116 proved half-life and glucose tolerance in an oral glucose tolerance test in rodents.

117 efficacious in lowering blood glucose in an oral glucose tolerance test in ZDF rats.

118 nge in glucose tolerance estimated by a 75-g oral glucose tolerance test result.

119 On the basis of oral glucose tolerance test results, participants were g

120 = 292), and Hispanics (n = 34) underwent an oral glucose tolerance test to assess whole-body insulin

121 e levels in healthy adults during a standard oral glucose tolerance test via exhaled VOC analysis.

122 An oral glucose tolerance test was administered at discharg

123 f insulin resistance (HOMA-IR); and a 2-hour oral glucose tolerance test was administered.

124 Oral glucose tolerance test was considered the gold stan

125 Oral glucose tolerance test was performed within 2 weeks

126 sensitivity and rate sensitivity during the oral glucose tolerance test were measured with the model

127 and 2-hour glucose levels measured during an oral glucose tolerance test were used to assess glycemic

128 control participants underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood

129 A total of 1,437 individuals underwent an oral glucose tolerance test with measurements of circula

130 of NAFLD patients underwent liver biopsy, an oral glucose tolerance test with minimal model analysis

131 okines, and cytokeratin-18 fragments, and an oral glucose tolerance test with minimal model analysis

132 cose tolerance (area under the curve for 3-h oral glucose tolerance test) 28% (P < 0.05), and plasma

133 (including results of a 26-28 week gestation oral glucose tolerance test) of women from the Born in B

134 G) ingested a labeled meal and 75 g glucose (oral glucose tolerance test) on separate occasions.

135 d ALT, AST, and GGT in 451 nondiabetic (75-g oral glucose tolerance test) Pima Indians (aged 30 +/- 6

136 rum resistin levels in 113 nondiabetic (75-g oral glucose tolerance test) Pima Indians (ages 29 +/- 7

137 ulinemic clamp), and glucose tolerance (75-g oral glucose tolerance test) were measured in 55 Pima In

138 absorptiometry), glucose tolerance (by 75-g oral glucose tolerance test), insulin action (M; by hype

139 nd indirect calorimetry), glucose tolerance (oral glucose tolerance test), serum lipid profile, and d

140 cases were diagnosed (49.1% on the basis of oral glucose tolerance test).

141 changes in portal insulin (as measured by an oral glucose tolerance test).

142 c insulin extraction from a mixed-meal or an oral glucose tolerance test).

143 Of 1319 people who were screened with an oral glucose tolerance test, 196 (15%) had impaired gluc

144 All underwent an oral glucose tolerance test, a liver panel, and a lipid

145 y insulin area under the curve (AUC) from an oral glucose tolerance test, aerobic fitness (peak oxyge

146 asured after an overnight fast and during an oral glucose tolerance test, and abdominal, thoracic, an

147 se in the glucose area under the curve in an oral glucose tolerance test, and AcAc predicted the conv

148 ions, 2-hour glucose concentrations using an oral glucose tolerance test, and an HbA1c level were sim

149 glucose and lipid levels, the results of an oral glucose tolerance test, and blood pressure were use

150 ulation (O-BP) using a clinical examination, oral glucose tolerance test, and gene expression and DNA

151 glucose (G-AUC) area under the curve during oral glucose tolerance test, and the Belfiore and Stumvo

152 bA1c and plasma glucose concentrations in an oral glucose tolerance test, and thus impaired beta cell

153 rwent clinical laboratory testing, including oral glucose tolerance test, and ultrasonographic invest

154 lucose sensitivity) were derived from a 75-g oral glucose tolerance test, and whole-body insulin sens

155 g insulin and glucagon concentrations during oral glucose tolerance test, and, in vitro, by measuring

156 were evaluated annually for 4 years with an oral glucose tolerance test, applying American Diabetes

157 RSM with three predonation RFs (oral glucose tolerance test, basal insulin, fasting plas

158 excursion between the groups of mice during oral glucose tolerance test, but insulin concentrations

159 hour glucose (beta = 0.46, P = 0.00090) post oral glucose tolerance test, but only the latter passed

160 glucose area under the curve (AUC) during an oral glucose tolerance test, correlated with MFAUp (r=0.

161 mnography, a multiple sleep latency test, an oral glucose tolerance test, determination of body fat b

162 ucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin leve

163 ucose levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin leve

164 In the oral glucose tolerance test, IL-1betaAb-treated CDs-HSD

165 clinical and anthropometric examinations, an oral glucose tolerance test, overnight urine collection,

166 In an oral glucose tolerance test, the 0- to 120-min glucose i

167 In the oral glucose tolerance test, the chloroform extract exer

168 years of age, without diabetes by history or oral glucose tolerance test, was done between 1992 and 1

169 asma glucose and hemoglobin A1c than for the oral glucose tolerance test, we suggest an alternative d

170 ts (5 men), as determined by a standard 75-g oral glucose tolerance test, were recruited to determine

171 ulin clearance were estimated by means of an oral glucose tolerance test, whereas peripheral insulin

172 tly associated with glucose levels during an oral glucose tolerance test, with the same SNP (rs642734

173 odel assessment of insulin resistance and an oral glucose tolerance test-based index (Matsuda insulin

174 with euglycemic-hyperinsulinemic clamp- and oral glucose tolerance test-based measures of insulin re

175 In the independent cohort, only oral glucose tolerance test-derived indexes were associa

176 ting glucose, fasting glucose or insulin, or oral glucose tolerance test-derived measures.

177 le, and 2-hour glucose was measured after an oral glucose tolerance test.

178 ce or impaired fasting glucose determined by oral glucose tolerance test.

179 sulin concentrations were measured during an oral glucose tolerance test.

180 llary blood glucose test, and a confirmatory oral glucose tolerance test.

181 glucose homeostasis measured by means of an oral glucose tolerance test.

182 All subjects had a standard oral glucose tolerance test.

183 with insulin and glucose levels during a 3-h oral glucose tolerance test.

184 Subjects were categorized based on a 75-g oral glucose tolerance test.

185 relatively normal glucose disposal during an oral glucose tolerance test.

186 ls and improved glycemic excursion during an oral glucose tolerance test.

187 tion (JDF) units or more, and a non-diabetic oral glucose tolerance test.

188 s obtained in the fasting state or during an oral glucose tolerance test.

189 (I0, I120) concentrations obtained during an oral glucose tolerance test.

190 viously undiagnosed diabetes, 4.7%) using an oral glucose tolerance test.

191 ed glucose tolerance after oral dosing in an oral glucose tolerance test.

192 of the measures assessed by using a standard oral glucose tolerance test.

193 C-glucose) in the basal state and during an oral glucose tolerance test.

194 eversal of diabetes; mice were then given an oral glucose tolerance test.

195 51 and 629 women, respectively, completed an oral glucose tolerance test.

196 ncentration also increases in response to an oral glucose tolerance test.

197 clamp with measurement of glucose turnover; oral glucose tolerance test; and a liver biopsy.

198 rves of glucose and insulin levels during an oral glucose tolerance test; levels of low-density lipop

199 r flowmetry), and glucose metabolism status (oral glucose tolerance test; normal glucose metabolism [

200 rimester of pregnancy (2-h glucose after the oral glucose tolerance test; r(s) </= -0.21, P < 0.05).

201 All subjects underwent a two-hour oral glucose-tolerance test (1.75 g [corrected] of gluco

202 tes mellitus (i.e., an abnormal result on an oral glucose-tolerance test but a fasting glucose level

203 28; aged 26 +/- 2 y) were tested with a 5-h oral-glucose-tolerance test (OGTT) and a euvolemic, euen

204 Intravenous-glucose-tolerance tests and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-

205 itivity was measured by fasting and 2-h post-oral-glucose-tolerance test (OGTT) insulin, the homeosta

206 g/m(2)) of 22.4 +/- 0.8 were subjected to an oral-glucose-tolerance test (OGTT) on 4 separate days wi

207 consumption (P = 0.07) and glycemia after an oral-glucose-tolerance test (P = 0.10) trended toward be

208 he curve of insulin and glucose after a 75-g oral-glucose-tolerance test after 4 mo of treatment.

209 Participants (n = 170) underwent a 3-h oral-glucose-tolerance test at 30 wk (95% CI: 25, 33 wk)

210 inistered questionnaires, by fasting and 2-h oral-glucose-tolerance test blood glucose measurement at

211 nsulin and glucose concentrations during the oral-glucose-tolerance test increased significantly afte

212 (P = 0.02), and the fasting insulin and the oral-glucose-tolerance test insulin area under the curve

213 ept for a reduced insulinemic response to an oral-glucose-tolerance test over time with daily breakfa

214 and 2-h glucose and insulin areas during the oral-glucose-tolerance test were similar across treatmen

215 NAFLD patients underwent a liver biopsy, an oral-glucose-tolerance test with minimal model analysis

216 glycemia (glucose area under the curve in an oral-glucose-tolerance test).

217 , a fasting blood glucose measurement, a 2-h oral-glucose-tolerance test, and record linkage to a rei

218 or glucose and insulin were assessed with an oral-glucose-tolerance test.

219 fasting insulin resistance index and with an oral-glucose-tolerance test.

220 0.0011), and 120 min (P = 0.0007) during the oral-glucose-tolerance test.

221 SD age: 21 +/- 11 y) in conjunction with an oral-glucose-tolerance test.

222 t a 5-y follow-up visit was assessed with an oral-glucose-tolerance test.

223 assessed by using the Matsuda method from an oral-glucose-tolerance test.

224 inistered questionnaires; by fasting and 2-h oral-glucose-tolerance-test blood glucose measurement at

225 All subjects were characterized by oral glucose tolerance testing (OGTT) and National Diabe

226 Oral glucose tolerance testing (OGTT) has been mooted as

227 .3 kg/m(2), 66 women, 35 men) underwent 75-g oral glucose tolerance testing (OGTT), body composition

228 All animals underwent oral glucose tolerance testing (OGTT).

229 screening in the early postpartum period via oral glucose tolerance testing after GDM, which is a tim

230 Participants underwent oral glucose tolerance testing based on WHO definitions

231 definition, despite not requiring the use of oral glucose tolerance testing or measures of IR or micr

232 is unique because diabetes was determined by oral glucose tolerance testing rather than by self-repor

233 ment was associated with the need to perform oral glucose tolerance testing upon study completion, by

234 Oral glucose tolerance testing with glucose, insulin, an

235 tly correlated with glucose responses during oral glucose tolerance testing, HbA1c, beta-cell functio

236 lipids, we performed lipid profiling during oral glucose tolerance testing, pharmacologic interventi

237 However, the glycemic response to oral glucose tolerance testing, the acute insulin respon

238 The latter is detected by oral glucose tolerance testing.

239 hropometry, and plasma glucose levels during oral glucose tolerance testing.

240 ea under the curve for glucose during 2-hour oral glucose tolerance testing.

241 ow-up for 2 years that included 2-hour, 75-g oral glucose tolerance testing; anthropometry; and inter

242 15 centers in nine countries underwent 75-g oral glucose-tolerance testing at 24 to 32 weeks of gest

243 Diabetes was diagnosed by annual oral-glucose-tolerance testing and semiannual fasting pl

244 persons without diabetes) was determined by oral-glucose-tolerance testing of the sample aged 40-74

245 abetic renal transplant recipients underwent oral glucose tolerance tests (OGTT) in 2005 to 2006 (bas

246 after death and who had undergone 2 or more oral glucose tolerance tests (OGTT) using grouped analys

247 pharmacodynamic endpoints were explored with oral glucose tolerance tests (OGTT), serum lipid profile

248 ave 2-h glucose values >11.1 mmol/l on their oral glucose tolerance tests (OGTT).

249 homeostasis by fasting blood glucose and/or oral glucose tolerance tests (OGTT).

250 To examine this possibility, we performed oral glucose tolerance tests (OGTTs) and euglycemic-insu

251 Oral glucose tolerance tests (OGTTs) and frequently samp

252 Oral glucose tolerance tests (OGTTs) and intravenous glu

253 Oral glucose tolerance tests (OGTTs) from differing stat

254 their associations with glucose levels from oral glucose tolerance tests (OGTTs) in pregnancy have n

255 sma glucose was measured every 3 months, and oral glucose tolerance tests (OGTTs) were performed annu

256 subjects with the E/E genotype underwent 5-h oral glucose tolerance tests (OGTTs), graded glucose inf

257 n of postchallenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that

258 tralizing antibody was administered prior to oral glucose tolerance tests (OGTTs).

259 insulinemia, by combining microdialysis with oral glucose tolerance tests and euglycemic-hyperinsulin

260 female obese Zucker (fa/fa) rats using both oral glucose tolerance tests and hyperinsulinemic-euglyc

261 nd enhanced suppression of plasma FFA during oral glucose tolerance tests and insulin clamp in obese

262 insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end.

263 Oral glucose tolerance tests at discharge revealed that

264 us adipose tissue biopsies were obtained and oral glucose tolerance tests conducted.

265 n CHD at baseline and had > or =2 (mean 4.2) oral glucose tolerance tests during follow-up.

266 and demonstrated blood glucose reductions in oral glucose tolerance tests in both C57BL/6J mice and h

267 significantly improved glycemic response to oral glucose tolerance tests in CNTF(Ax15)-treated UCP1-

268 sma glucose responses were higher during the oral glucose tolerance tests in patients with IDCM (p <

269 receiving neuroleptic medication were given oral glucose tolerance tests involving serial glucose an

270 We studied this progression using biennial oral glucose tolerance tests performed in the Baltimore

271 All underwent oral glucose tolerance tests pre-LTx and serially post-L

272 Oral glucose tolerance tests revealed that male Znt7 KO

273 Oral glucose tolerance tests were administered at the sa

274 od samples were collected in the morning and oral glucose tolerance tests were done in accordance wit

275 Oral glucose tolerance tests were performed annually on

276 Fasting glucose was measured quarterly, and oral glucose tolerance tests were performed annually.

277 Physical examinations and oral glucose tolerance tests were performed at baseline

278 Modified oral glucose tolerance tests were performed in schizophr

279 Oral glucose tolerance tests were performed in the 43 pa

280 Oral glucose tolerance tests were performed to examine t

281 ed; and (3) peak blood glucose levels during oral glucose tolerance tests were significantly reduced.

282 In oral glucose tolerance tests with diet-induced obese mic

283 ed insulin sensitivity, show improvements in oral glucose tolerance tests, display reduced adipose ti

284 asting or non-fasting plasma glucose levels, oral glucose tolerance tests, hemoglobin A1C levels, and

285 linemic-euglycemic clamp and intravenous and oral glucose tolerance tests.

286 Insulin kinetics were calculated from oral glucose tolerance tests.

287 16.6 mumol/L v 131.7 mumol/L; P = 0.09), and oral glucose tolerance tests.

288 We measured steroids in serum and performed oral glucose-tolerance tests before and after the oral a

289 Participants were diagnosed by 75 g oral glucose-tolerance tests.

290 h measures collected from frequently sampled oral-glucose-tolerance tests (OGTTs).Twenty-seven of 29

291 se, insulin, and C-peptide measured by using oral-glucose-tolerance tests at the end of each diet.

292 resistance and sensitivity were defined from oral-glucose-tolerance tests in 86 overweight and obese

293 d hormone concentrations, and results of 3-h oral-glucose-tolerance tests were examined in obese and

294 diabetes were verified by record tracing and oral-glucose-tolerance tests.

295 a low-fat diet were genotyped and underwent oral-glucose-tolerance tests.

296 Diabetes status was assessed by using oral-glucose-tolerance tests.

297 Impaired oral glucose tolerance was associated with insulin resis

298 Enhanced oral glucose tolerance was noted in TG mice by a reduced

299 After each 4-wk diet, serum lipids and oral glucose tolerance were measured.

300 In normal rats, compound 2 improved oral glucose tolerance with significant reduction in ins